Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2019-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-AstraZeneca-Amend-LINZESS-linaclotide-Collaboration-in-China/default.aspx
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-AstraZeneca-Amend-LINZESS-linaclotide-Collaboration-in-China/default.aspx
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-September-Investor-Conferences/default.aspx
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-September-Investor-Conferences/default.aspx
Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Full-Exercise-of-Convertible-Notes-Over-Allotment/default.aspx
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-Alnylam-Pharmaceuticals-Enter-US-GI-Disease-Education-and-Promotional-Agreement-for-Alnylams-Givosiran-in-Acute-Hepatic-Porphyria-AHP/default.aspx
Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Full-Exercise-of-Convertible-Notes-Over-Allotment/default.aspx
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-Alnylam-Pharmaceuticals-Enter-US-GI-Disease-Education-and-Promotional-Agreement-for-Alnylams-Givosiran-in-Acute-Hepatic-Porphyria-AHP/default.aspx
Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Pricing-of-Upsized-350-Million-Convertible-Senior-Notes-Offering/default.aspx